<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03683407</url>
  </required_header>
  <id_info>
    <org_study_id>COTMB</org_study_id>
    <nct_id>NCT03683407</nct_id>
  </id_info>
  <brief_title>Effect of Chemotherapy on TMB in NSCLC</brief_title>
  <official_title>Effect of Platinum-based Chemotherapy on Tumor Mutation Burden in Patients With Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baodong Qin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Changzheng Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tumor mutation burden is identified as an important biomarkers for predicting PD-1/PD-L1
      inhibitors in advanced Non-Small Cell Lung Cancer. Several previous clinical trials have
      demonstrated that chemotherapy could enhance the efficacy of PD-1/L1 immunotherapy in NSCLC
      such as Checkmate-227, Impower-150, Keynote-189, etc. Pre-clincial experiment shows that
      chemotherapy could increase CD8 TIL infiltration in tumor microenvironment, activate T cell
      immune reaction. However, it remains unclear whether chemotherapy could affect tumor mutation
      burden in advanced NSCLC patients. The present study aims to evaluate whether tumor mutation
      burden will change after receiving chemotherapy in advanced NSCLC patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor Mutation Burden Change</measure>
    <time_frame>every 6 weeks up to progression disease</time_frame>
    <description>Tumor mutation burden will be calculated using a 520 genes NGS panel</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chemotherapy Effect</condition>
  <condition>Immunotherapy</condition>
  <condition>Tumor Mutation Burden</condition>
  <condition>PD-1/L1 Inhibitor</condition>
  <arm_group>
    <arm_group_label>Chemotherapy Group</arm_group_label>
    <description>All participants are advanced NSCLC without druggable gene mutation (EGFR, ALK, ROS-1, Met, Ret. BRAF, etc), who would receive platinum-based chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Next-Genernation Sequence</intervention_name>
    <description>Tumor Mutation burden will be evaluated using NGS after 2-cycle chemotherapy, 4-cycle chemotherapy, or at progressive disease</description>
    <arm_group_label>Chemotherapy Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA from tumor tissue or circulating Tumor DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Advanced NSCLC without druggable molecular events (EGFR, ALK, c-Met, BRAF, Ret, etc)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced NSCLC diagnosed histologically; Expected survival ≥ 6 month;

          -  Without Druggable molecular events (EGFR, ALK, c-Met, BRAF, Ret, etc)

          -  ECOG / PS score: 0-2, and the main organ function to meet the following criteria: HB ≥
             90g / L, ANC ≥ 1.5 × 109 / L, PLT ≥ 80 × 109 / L,BIL &lt;1.5 times the upper limit of
             normal (ULN); Liver ALT and AST &lt;2.5 × ULN and if liver metastases, ALT and AST &lt;5 ×
             ULN; Serum Cr ≤ 1 × ULN, endogenous creatinine clearance ≥50ml/min

        Exclusion Criteria:

          -  Patient can not comply with research program requirements or follow-up;

          -  Patient will receive immunotherapy;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiao-Dong Jiao, MD</last_name>
      <phone>+86-13817797639</phone>
      <email>pulava@139.com</email>
    </contact>
    <investigator>
      <last_name>Yuan-Sheng Zang, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 16, 2018</study_first_submitted>
  <study_first_submitted_qc>September 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2018</study_first_posted>
  <last_update_submitted>September 23, 2018</last_update_submitted>
  <last_update_submitted_qc>September 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Changzheng Hospital</investigator_affiliation>
    <investigator_full_name>Baodong Qin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

